Logo image
返回
An Open‐Label, Single‐Arm, Two‐Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas
期刊文章   同儕審查

An Open‐Label, Single‐Arm, Two‐Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas

Ming‐Huang Chen, Wen‐Chi Chou, Chin‐Fu Hsiao, Shih Sheng Jiang, Hui‐Jen Tsai, Yi‐Chang Liu, Chiun Hsu, Yan‐Shen Shan, Yi‐Ping Hung, Chia‐Hsun Hsich, …
The oncologist (Dayton, Ohio), 卷.25(5), 頁碼.e782-e788
05/2020
DOI: https://doi.org/10.1634/theoncologist.2019-0490
PMID: 31852810
Web of Science ID: WOS:000503105300001

摘要

Endocrinology
This article reports on the efficacy and safety of TLC388 in a second‐line setting for patients with poorly differentiated neuroendocrine carcinomas.

檔案與連結 (1)

url
https://doi.org/10.1634/theoncologist.2019-0490檢視
已出版(紀錄版本) 開放

相關連結

指標

1 檢視次數
11 被引用次數 - Web of Science

詳細資料

Logo image